ConvaTec (CTEC) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $1.8B

Founded: 1978Employees: 8,000-9,000HQ: London, United Kingdom

Overview

ConvaTec's mission is to improve the lives of people with chronic conditions through pioneering products and support services. The company has achieved sustained growth by building trusted, long-term relationships with patients and clinicians, underpinned by its core Hydrofiber® technology and comprehensive service platforms like me+™. Its strategy focuses on accelerating organic growth through innovation in its four core franchises, expanding in high-growth markets, and driving operational excellence to support margin expansion.

Wound CareOstomy CareContinence CareCritical CareInfusion Care

Technology Platform

ConvaTec's core technology is its proprietary Hydrofiber® platform for advanced wound care, complemented by deep expertise in skin-friendly adhesives, catheter design, infusion sets, and integrated digital patient support ecosystems like me+™.

Funding History

1

Total raised:$1.8B

IPO$1.8BUndisclosedOct 25, 2016

Opportunities

ConvaTec is positioned to capitalize on powerful demographic trends (aging population, rise in chronic diseases) driving growth in its core markets.

Expanding its digital service platform (me+™) and launching next-generation products in wound and ostomy care present significant avenues for market share gains and deeper patient engagement, particularly in underpenetrated emerging economies.

Risk Factors

The company faces persistent pricing and reimbursement pressure from global healthcare systems, intense competition (notably from Coloplast in ostomy care), and regulatory complexities associated with medical devices.

Execution risks on its growth strategy and potential supply chain disruptions also pose challenges to financial targets.

Competitive Landscape

ConvaTec operates in competitive, consolidating markets. Its primary rivals include Coloplast (ostomy, wound), Smith & Nephew and 3M (wound care), and BD (infusion, continence). Competition is based on product innovation, clinical evidence, cost-effectiveness, and, increasingly, integrated service offerings.